 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C11H11Cl2N |
| Molar mass | 228.12 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
DOV 216,303 is an experimentalantidepressantdrug originally developed byDOV Pharmaceutical and was licensed toMerck & Co. in 2004;[1] Merck and DOV terminated their relationship in December 2006.[2]: 12 [3]
It is atriple reuptake inhibitor (TRI), orserotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).[4] It is theracemic mixture ofamitifadine (DOV-21,947) and its (–)-enantiomer,DOV-102,677. ItsIC50 values forSERT,NET, andDAT are Ki 14 nM, 20 nM, and 78 nM, respectively.[4]
As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.[2]: 6
In amouse model, DOV-216,303 has shown the ability to promote recovery after spinal cordcontusion.[5]
DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.